Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330561 · ClinicalTrials.gov registry record · Phase 1
PRS-343 in HER2-Positive Solid Tumors
A Phase 1 study, sponsored by Pieris Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT03330561 is a Phase 1 study that has completed, run by Pieris Pharmaceuticals. The registered enrollment target is 85 participants.
The verdict
NCT03330561, a Phase 1 study, has completed, sponsored by Pieris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
Interventions
- DRUG PRS-343
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330561
The ClinicalTrials.gov registry entry for NCT03330561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pieris Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRS-343 is the first listed.
NCT03330561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330561 about?
NCT03330561 is a clinical study titled "PRS-343 in HER2-Positive Solid Tumors". A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
What is the current status of trial NCT03330561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2017-09-13. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT03330561?
The interventions under investigation include: PRS-343 (DRUG).
Who is sponsoring clinical trial NCT03330561?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.